Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium Bridging the Lab and the Clinic in Cancer Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gillespie, S.
Right arrow Articles by Hersey, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gillespie, S.
Right arrow Articles by Hersey, P.
Mol Cancer Ther. 2005;4:668-676
© 2005 American Association for Cancer Research

Variable expression of protein kinase C{varepsilon} in human melanoma cells regulates sensitivity to TRAIL-induced apoptosis

Susan Gillespie, Xu Dong Zhang and Peter Hersey

Immunology and Oncology Unit, Newcastle Mater Hospital, Newcastle, New South Wales, Australia

Requests for reprints: Peter Hersey, Immunology and Oncology Unit, Mater Hospital, Room 443, David Maddison Clinical Sciences Building, Corner King & Watt Streets, Newcastle, New South Wales 2300, Australia. Phone: 61-2-49-236828; Fax: 61-2-49-236184. E-mail: Peter.Hersey{at}newcastle.edu.au

Protein kinase C (PKC) activation is believed to protect against apoptosis induced by death receptors. We have found however that the effect of activation of PKC on tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)–induced apoptosis of melanoma differs between cell lines. Pretreatment with phorbol 12-myristate 13-acetate (PMA) led to inhibition of apoptosis in the majority of the melanoma cell lines, but those with relatively low PKC{varepsilon} expression were sensitized to TRAIL-induced apoptosis. Introduction of PKC{varepsilon} into PKC{varepsilon}-low cell lines reversed sensitization of the cells to TRAIL-induced apoptosis by PMA. In contrast, a dominant-negative form of PKC{varepsilon} caused an increase in sensitivity. The changes in sensitivity to TRAIL-induced apoptosis were reflected in similar changes in conformation of Bax and its relocation from the cytosol to mitochondria. Similarly, there were concordant increases or decreases in mitochondrial release of second mitochondria-derived activator of caspase/DIABLO, activation of caspase-3, and processing of its substrates. Activation of PKC seemed to mediate its effects upstream of mitochondria but downstream of caspase-8 and Bid in that pretreatment with PMA did not cause significant changes in the expression levels of TRAIL death receptors, alterations in the levels of caspase-8 activation, or cleavage of Bid. PKC activated the antiapoptotic extracellular signal-regulated kinase 1/2 pathway, but inhibitors of this pathway only partially reversed the protective effect of PKC against TRAIL-induced apoptosis. These results provide further insights into the variable responses of melanoma to TRAIL-induced apoptosis and may help define responsive phenotypes to treatment of melanoma with TRAIL.


Key Words: Melanoma • TRAIL • Apoptosis • Protein kinase C

Grant support: State Cancer Council, New South Wales, Australia.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 12/10/04; revised 1/21/05; accepted 2/ 7/05.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
S. Abbas, A. Bhoumik, R. Dahl, S. Vasile, S. Krajewski, N. D.P. Cosford, and Z. A. Ronai
Preclinical Studies of Celastrol and Acetyl Isogambogic Acid in Melanoma
Clin. Cancer Res., November 15, 2007; 13(22): 6769 - 6778.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
N. M. Mhaidat, R. F. Thorne, X. D. Zhang, and P. Hersey
Regulation of Docetaxel-Induced Apoptosis of Human Melanoma Cells by Different Isoforms of Protein Kinase C
Mol. Cancer Res., October 1, 2007; 5(10): 1073 - 1081.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Lu, J. Huang, and A. Basu
Protein Kinase C{epsilon} Activates Protein Kinase B/Akt via DNA-PK to Protect against Tumor Necrosis Factor-{alpha}-induced Cell Death
J. Biol. Chem., August 11, 2006; 281(32): 22799 - 22807.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Mirandola, G. Gobbi, C. Ponti, I. Sponzilli, L. Cocco, and M. Vitale
PKC{epsilon} controls protection against TRAIL in erythroid progenitors
Blood, January 15, 2006; 107(2): 508 - 513.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.